Clinical trials: Cetuximab
Rectal Cancer
Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy
(1) To evaluate the oncological effects of Treatment of low locally advanced rectal cancer with radiotherapy removal TNT plus neoadjuvant therapy TNT plus mode on TRG, Anal sphincter preservation surgery rate / rectal…
- Trial name
- NCT06035133
- Testing
- CapeOX + cetuximab, CapeOX + bevacizumab, radiotherapy
- Volunteers
- 213 people
- Sponsor
- Tang-Du Hospital
Colorectal Cancer
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
Open-label phase 1b trial. Study treatment will be administered in 3 week cycles. There are two distinct parts in this study: Part 1: Dose escalation from IMO-2055 Part 2: Once a recommended phase 2 dose is found additional…
- Trial name
- NCT00719199
- Testing
- IMO-2055, Cetuximab, FOLFIRI
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- EMD Serono
Colorectal Cancer, Peritoneal Metastases
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
- Conditions
- Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
- Trial name
- NCT07411599
- Testing
- Cyclophosphamide, Fludarabine, Cetuximab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Head and Neck
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
A phase III trial of induction chemotherapy followed by definitive radiotherapy plus Cetuximab versus chemoradiation in unresectable, locally advanced, squamous cell carcinoma of the head and neck (HNC).
- Trial name
- INTERCEPTOR (NCT00999700)
- Testing
- docetaxel - cisplatin - 5-fluorouracil, radiotherapy, cetuximab
- Where
- 21 sites in Italy
- Volunteers
- 282 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Advanced Colorectal Cancer, Small Intestinal Cancer
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced…
- Conditions
- Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
- Trial name
- NCT05194995
- Testing
- JAB-21822, Cetuximab
- Where
- 17 sites in China
- Volunteers
- 48 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Rash Due to Epidermal Growth Factor Receptor Inhibitors
Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients
The purpose of this study is to evaluate the safety, tolerability and efficacy of FDX104 Antibiotic Foam in the prevention of EGFRI skin toxicity in cancer patients receiving Cetuximab or Panitumumab.
- Trial name
- NCT02239731
- Testing
- FDX104 (4% Doxycycline)
- Where
- 7 sites in Israel
- Volunteers
- 24 people
- Sponsor
- Vyne Therapeutics Inc.
Colorectal Cancer
Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in…
- Trial name
- CELIM2 (NCT01802645)
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 15 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Technische Universität Dresden
Carcinoma, Squamous, Squamous Cell Carcinoma
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
This study evaluates the combination of BYL719, cisplatin and cetuximab as induction chemotherapy prior to minimally-invasive transoral surgery (TORS or TLM) and selective lymph node dissection (SLND), followed by risk-adapted…
- Conditions
- Carcinoma, Squamous, Squamous Cell Carcinoma, Oropharyngeal Neoplasms, Oropharyngeal Cancer
- Trial name
- NCT02298595
- Testing
- cisplatin, Cetuximab, BYL719
- Sponsor
- Julie E. Bauman, MD, MPH
Colorectal Cancer
Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer.
3rd line standard treatment of patients with metastatic colorectal cancer (CRC) harboring K-ras wild type consists of anti-EGFR treatment with either cetuximab or panitumumab.
- Trial name
- NCT01691391
- Testing
- (Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Amsterdam UMC, location VUmc
Head and Neck Neoplasms, Neoplasm Metastasis
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
The aim of this study is to determine the activity, to assess the safety and tolerance of BKM120 in adult patients with recurrent or metastatic head and neck cancer progressive under platin and cetuximab-based chemotherapy.
- Conditions
- Head and Neck Neoplasms, Neoplasm Metastasis, Recurrent Disease, Progressive Disease
- Trial name
- PIK-ORL (NCT01737450)
- Testing
- BKM120
- Where
- 9 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Advanced Solid Tumors Cancer, PDAC
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
This is a Phase Ib/II clinical study aimed at exploring the safety and efficacy of Regimen A (GFH375 in combination with Cetuximab) and Regimen B (GFH375 in combination with AG) in participants with solid tumors.Phase Ib: To…
- Conditions
- Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
- Trial name
- NCT07259590
- Testing
- GFH375
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Head and Neck Neoplasms
Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Concomitant radio-chemotherapy has become a standard therapy for advanced squamous cell carcinomas of head and neck. Local side effects caused by chemotherapy, like mucositis, increase in combination with radiotherapy.
- Trial name
- NCT02015650
- Testing
- Cetuximab, Mitomycin-C/ 5-Fluorouracil
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Medical University Innsbruck
Squamous Cell Carcinoma of Head and Neck, Sinus Cancer
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer
- Trial name
- NCT07063212
- Testing
- Sacituzumab Govitecan, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00541112
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 10 sites in France
- Volunteers
- 19 people
- Sponsor
- UNICANCER
Folliculitis
Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis
The study aims to explore the benefit of topical vitamin K3 lotion for the reactivation/rephosphorylation of EGF-receptor in the skin and the possible reduction in cutaneous side effects of EGFr-inhibition.
- Trial name
- NCT01094444
- Testing
- Vitamin K3
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Per Pfeiffer
Metastatic Colorectal Cancer
A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer
The purpose of this study is to assess if panitumumab is active enough to warrant comparative studies in patients with metastatic colorectal cancer that has progressed after treatment with cetuximab.
- Trial name
- PACER (NCT01801904)
- Testing
- Panitumumab
- Where
- 5 sites in Italy
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute, Naples
Head and Neck Cancer
Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer
This is a study for patients with head and neck cancer who will be receiving chemotherapy and radiation therapy for their disease.
- Trial name
- PGx-SELECT (NCT00881114)
- Testing
- Cisplatin, Cetuximab
- Sponsor
- Georgetown University
Rectal Neoplasms
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
The purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with intravenous (IV) dalotuzumab (MK-0646) + irinotecan therapy relative to…
- Trial name
- NCT01609231
- Testing
- Dalotuzumab, Irinotecan, Cetuximab
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Unresectable, Locally Advanced
Cetuximab + Gemox in Biliary Tract Cancer
The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary…
- Conditions
- Unresectable, Locally Advanced, Metastatic
- Trial name
- NCT01216345
- Testing
- Cetuximab + Gemcitabine + Oxaliplatin
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Association of Research on the Biology of Liver Tumors
RAS Wild Type mCRC
Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer
This is a single-arm, single-center, exploratory study aimed at exploring the treatment of RAS wild-type recurrent/metastatic colorectal cancer with the combination of becotatug vedotin and cetuximab as a salvage therapy
- Trial name
- NCT07490119
- Testing
- Becotatug Vedotin, Cetuximab
- Volunteers
- 31 people
- Sponsor
- Fudan University